

CME Lunch Symposium

FRIDAY, SEPTEMBER 9

12:20 PM- 1:20 PM

The Disproportionate Burden of Heart Failure in Women: Advances & Expert Perspectives to Improve Diagnosis and Treatment



This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

PROGRAM OVERVIEW:

The prevalence of heart failure (HF) is greater in women compared to men; however, significant gaps exist in the management of women with heart failure. Compared to men, women with HF receive suboptimal guideline-directed medical therapy (GDMT), including medications, implantable cardioverter defibrillators, ventricular assist devices, or heart transplant. Additionally, despite a higher HF symptom burden, women are frequently misdiagnosed and also underrepresented in HF clinical trials, which further exacerbates these gaps. In recent years, significant advances in the prevention and treatment of HF have been made, all with the potential to alter treatment paradigms now and in the future. In this symposium, experts will review these gaps, as well as discuss how to apply the recent advances to improve the care of women with HF.

LEARNING OBJECTIVES:

After completing this activity, the participant should be better able to:

- Discuss the burden of HF in women, as well as differences in HF etiology and risk factors.
- Recognize the differences in HF symptom presentation in women in order to identify HF in a timely manner.
- Summarize important differences and considerations for the application of GDMT in women with HF.
- Review the efficacy and safety of new and emerging therapies for the treatment of women with HFrEF or HFpEF.
- Individualize therapy for women with HFrEF or HFpEF according to evidence-based strategies and patient specific risk factors.

The Disproportionate Burden of Heart Failure in Women: Advances & Expert Perspectives to Improve Diagnosis and Treatment

FACULTY CHAIR



Pam R. Taub, MD

Professor of Medicine
Director, Step Family Foundation Cardiac Rehabilitation and Wellness Center
UC San Diego
San Diego, CA

FACULTY



Michelle M. Kittleson, MD, PhD

Professor of Medicine
Smidt Heart Institute, Cedars-Sinai
Los Angeles, CA



Barry H. Greenberg, MD

Director, Advanced Heart Failure Treatment Program
University of California
San Diego, CA



Anuradha Lala-Trindade (Anu Lala), MD

Associate Professor, Icahn School of Medicine at Mount Sinai
The Zena and Michael A. Wiener Cardiovascular Institute
Department of Health Population Science and Statistics
New York, NY

The Disproportionate Burden of Heart Failure in Women: Advances & Expert Perspectives to Improve Diagnosis and Treatment

JOINT PROVIDERSHIP STATEMENT



This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 1 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST ACCREDITATION STATEMENT



Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Global Education Group designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number (UAN): 0530-9999-22-113-L01-P. This is a knowledge-based activity.

GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

The Disproportionate Burden of Heart Failure in Women: Advances & Expert Perspectives to Improve Diagnosis and Treatment

HOW TO REQUEST CE CREDIT

Learners may earn up to a maximum of 6.5 AMA/ACPE/ANCC/CDR credits for attending all General Sessions (earn up to 4.25 hours) and CME Satellite Symposia (earn up to 2.25 hours). For educational symposia support information, including accreditation, please review the CME symposia information on the mobile app.

An evaluation link will be provided post-meeting to all attendees of the Masterclass. Several email reminders will be sent post-meeting. Please claim your CE credits by completing the evaluation by Friday, September 30, 2022.

Upon completion of the CME/CE evaluation, attendees can download their general sessions certificate. For satellite symposia, certificates will be provided separately via email within 5-7 business days after the September 30 deadline.

For Pharmacists: Pharmacists have until the September 30 deadline to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required. Expect credit uploads to be completed within 5-7 business days after the evaluation deadline.

For questions regarding the evaluation, please contact: cmhc_eval@cardiometabolichealth.org

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is a registration fee for participating and receiving CME/CE credit for this educational activity. Registration information can be found [here](#).

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager	Reported Financial Relationship
Rhys Williams, MSN, FNP-C, RN	Nothing to disclose
Amanda Turner MS, RDN, CSSD	Nothing to disclose
Lindsay Borvansky	Nothing to disclose
Andrea Funk	Nothing to disclose
Liddy Knight	Nothing to disclose

The Disproportionate Burden of Heart Failure in Women: Advances & Expert Perspectives to Improve Diagnosis and Treatment

Ashley Cann	Nothing to disclose
Karin McAdams	Nothing to disclose
Shpetim Karandrea, PhD	Nothing to disclose
Neha Agarwal, PhD	Nothing to disclose

The faculty have the following relevant financial relationships with ineligible companies:

Name of Speaker	Reported Financial Relationship
Pam Taub, MD	Consulting Fee (e.g., Advisory Board): Applied Therapeutics, Amgen, Bayer, Boehringer-Ingelheim, Esperion therapeutics, Medtronic, Novartis, Novo-Nordisk, Sanofi Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Epirium Bio
Barry Greenberg, MD	Consulting Fee (e.g., Advisory Board): AstraZeneca, Bayer, Cytokinetics, Ionis, Merck, Tenaya Contracted Research: Rocket Pharma Honoraria: ACI, Axon, BoehringerIngelheim, Cytokinetics, EBR Systems, Impulse Dynamics, Inventiva, Ionis, Salubris, Vifor, Viking, Windtree
Anuradha Lala-Trindade (Anu Lala), MD	Consulting Fee (e.g., Advisory Board): Merck, Astra Zeneca, Cytokinetics, Novartis Honoraria: Merck, Astra Zeneca, Cytokinetics, Novartis
Michelle M. Kittleson, MD, PhD	Nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.